---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029847"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:40:15.836868+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin gets Canadian patent allowance for Annamycin manufacturing process; term to 2040

## Summary
- CIPO issued notice of allowance for patent application 3,142,510 covering preliposomal Annamycin lyophilizate preparation.
- Patent expected to issue in coming months; base term extends to June 2040, subject to regulatory extension.
- Company already holds issued U.S. and allowed European patents for Annamycin; additional applications pending globally.
- CEO states this strengthens global IP portfolio for Annamycin as a non-cardiotoxic anthracycline for AML and STS lung mets.

## SEC filing metadata
- accession: 0001437749-25-029847
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925029847/0001437749-25-029847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925029847/mbrx20250923_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029847
- JSON: https://secwatch.observer/filing/0001437749-25-029847.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.